Bracco Imaging S.p.A., Bayer HealthCare, and Guerbet Group to Dominate the Global Contrast Injector Market

-
A number of key players are competing against each other in order to expand their existing customer base. In 2015, the contrast injector market was dominated by Bracco Imaging S.p.A (Italy), Bayer HealthCare (Germany), and Guerbet Group (France). Other players in this market include GE Healthcare (U.S.), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), AngioDynamics (U.S.) Sino Medical- Device Technology Co., Ltd. (China), Apollo RT Co., Ltd. (China), VIVID IMAGING (China), and Nemoto Kyorindo Co., Ltd. (Japan).

Bracco Imaging S.p.A is dominating the contrast injector market in 2016. The company is engaged in the discovery, development, manufacturing, and commercialization of imaging solutions for diagnostic imaging procedures to amplify the anatomic and functional visualization of internal body organs and areas. It also provides advanced administration systems for contrast imaging products. In 2011, the company acquired Swiss Medical Care (SMC) (Switzerland), to strengthen its automated system for contrast media injectors. Similarly, in 2008 and 2001, it acquired Acist Medical System (U.S.) and E-Z-EM Canada, Inc. (Canada) respectively. Bracco Imaging S.p.A serves customers in the Americas, Europe, and the Rest of the World with an employee base of 3,400 and a portfolio of 1,800 patients. The company’s notable revenue is from the European region followed by North America and RoW. The company maintains a direct sales force to reach out to its customers. It succeeded in creating a strong foothold in the market, owing to its diversified product portfolio, wide geographic reach, and focus on acquisitions and product launch.
Bayer HealthCare is second largest player in the contrast injector market in 2016. The company deals in R&D activities along with the manufacturing and marketing of products. Bayer HealthCare has two reporting segments, namely, Pharmaceuticals and Consumer Health. The Pharmaceuticals segment deals in prescription products specifically for women’s health and cardiology and specialty therapeutics in the areas of oncology, hematology, and ophthalmology. The Consumer Health segment has three divisions: consumer care, medical care, and animal health. The medical care division comprises two business units— diabetes care and radiology. The radiology business unit offers contrast-enhanced diagnostic imaging equipment along with the necessary contrast agents. The company continuously strives to strengthen its market position in various geographies by focusing on expansion and acquisitions for its contrast media injector products. The company acquired Medrad Inc., (U.S.) in 2011; the acquisition enabled Bayer AG to leverage its injector technology. In March 2014, the company invested around USD 132.9 million (EUR 100 million) to increase the production capacity of its plant in Beijing, China. This establishment enabled the company to meet the growing demand for its products by customers in China.
Guerbet Group is third largest player in the contrast injector market in 2016. The company is mainly focused on manufacturing and commercializing medical imaging contrast agents intended for diagnostic purposes. The company provides a wide range of contrast agents for X-ray examinations, MRI, and nuclear medicine. The company strives to strengthen its market position in various geographies by focusing on approval and acquisitions for its contrast injector products. For instance, the company acquired Mallinckrodt’s Contrast Media and Delivery Systems (CMDS) business for USD 270 million. The acquisition enabled Guerbert to serve new geographies like Australia and South Africa. The company also focuses on innovation and received awards for its contrast media injector products. For instance, in 2015, the company received an award from Red Dot Design for product design and New Product Innovation Award from Frost & Sullivan. Its wide range of product offerings, extensive geographic reach, and focus on innovation are contributing to the company’s large share in the market. The company has strong presence in EMEA (Europe, the Middle East, and Africa) countries followed by North America, APAC, and LATAM.
Other players operating in this market adopted the strategy of agreements, partnerships, and acquisitions, expansions, product launches, grants, product deployment, and approvals to increase their customer base across geographies and establish a strong foothold in the market.
Related Reports:

Contrast Injector Market by Product (Injector Systems (CT Injector, MRI Injector), Consumables (Injector Head, Tubing), Accessories), & Application (Radiology, Interventional Cardiology, Interventional Radiology) - Global Forecast to 2021 

Location: Northbrook, IL 60062, USA

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more